Skip to main content

Table 4 Predictors of MS among PLWHIV at follow up in Jimma health centre ART clinic, April 01 to May 30, 2016

From: Prevalence and predictors of metabolic syndrome among people living with human immunodeficiency virus (PLWHIV)

Variables

MS according to (NCEP-ATP III)

Bivariate analysis

Multivariate analysis

p value

COR (95% CI)

p value

AOR (95% CI)

Yes

No

Sex

 Male

12

45

0.623

0.837 (0.411–1.703)

  

 Female

51

160

1

1

  

Age in years

 18–30

8

52

1

1

1

1

 31–40

24

85

0.172

1.835 (0.768–4.387)

0.538

1.358 (0.513–3.594)

 41–50

20

41

0.014

3.171 (1.268–7.928)

0.175

2.058 (0.725–5.847)

 ≥ 51

11

27

0.062

2.648 (0.953–7.362)

0.344

1.782 (0.539–5.894)

Able to write or read

 No

17

79

0.097

0.589 (0.316–1.099)

0.979

1.014 (0.355–2.899)

 Yes

46

126

1

1

1

1

Formal education

 Yes

54

143

1

1

1

1

 No

9

62

0.014

0.384 (0.179–0.827)

0.031

0.252 (0.072–0.879)

Smoking history

 No

61

192

1

1

  

 Yes

2

13

0.349

0.484 (0.106–2.206)

  

Past Khat chewer

 No

46

133

1

1

1

1

 Yes

17

72

0.232

0.683 (0.365–1.277)

0.583

0.813 (0.388–1.704)

Current Khat chewer

 No

14

58

1

1

  

 Yes

3

14

0.865

0.888 (0.224–3.517)

  

Alcohol consumption

 No

39

127

1

1

  

 Yes

24

78

0.995

1.002 (0.560–1.792)

  

Frequency of alcohol

 1–4 days/weeks

11

27

1

1

  

 1–3 days/weeks

8

30

0.428

0.655 (0.229–1.868)

  

 < Once a month

5

21

0.381

0.584 (0.176–1.943)

  

Physical activity

 Inactive

40

101

1

1

1

1

 Active

23

104

0.050

0.558 (0.312–0.999)

0.325

0.702 (0.347–1.420)

Fruit intake

 None

23

55

1

1

1

1

 1–2 days/week

27

98

0.206

0.659 (0.345–1.258)

0.103

0.513 (0.230–1.145)

 3–4 days/week

9

32

0.380

0.673 (0.277–1.630)

0.621

0.767 (0.269–2.190)

 5–7 days/week

4

20

0.220

0.478 (0.147–1.554)

0.334

0.513 (0.132–1.986)

Comorbid disease

 No

53

187

1

1

1

1

 Yes

10

18

0.112

1.960 (0.854–4.500)

0.543

1.383 (0.486–3.930)

Duration of HIV

 ≤ 5 years

15

107

< 0.001

0.286 (0.151–0.543)

0.136

0.482 (0.185–1.259)

 > 5 years

48

98

1

1

1

1

CD4 (cell/mm3)

 < 350

53

170

1

1

  

 351–550

9

29

0.991

0.995 (0.443–2.235)

  

 ≥ 551

1

6

0.566

0.535 (0.063–4.541)

  

WHO stages

 Stage I

12

35

1

1

  

 Stage II

28

101

0.592

0.809 (0.371–1.760)

  

 Stage III

21

63

0.946

0.972 (0.428–2.209)

  

 Stage IV

2

6

0.975

0.972 (0.172–5.481)

  

Duration of cART

 ≤ 5 years

26

137

1

1

1

1

 > 5 years

36

63

< 0.001

3.011 (1.676–5.410)

0.372

1.563 (0.586–4.173)

 Othersa

1

5

0.963

1.054 (0.118–9.394)

0.735

1.499 (0.143–15.666)

Types of cART

 D-drugsb

33

56

< 0.001

2.927 (1.635–5.238)

0.366

1.591 (0.581–4.360)

 Othersc

30

149

1

1

1

1

BMI (kg/m2)

 < 18.5

6

44

1

1

1

1

 18.5–24.9

37

147

0.195

1.846 (0.731–4.660)

0.129

2.191 (0.795–6.036)

 ≥ 25

20

14

< 0.001

10.47 (3.513–31.24)

< 0.001

13.398 (3.943–45.525)

  1. COR crude odd ratio, AOR adjusted odd ratio, HIV human immunodeficiency virus, CD4 cluster determinant 4, WHO world health organization, cART combination antiretroviral therapy, BMI body mass index, d4T stavudine, 3TC lamivudine, AZT zidovudine, TDF tenofovir, NVP nevirapine, EVF efavirenz
  2. aNaïve patients
  3. bd4T + 3TC + NVP/or EVF
  4. cAZT/or TDF + 3TC + NVP/or EVF and naïve patients
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us